TRBV26OR9-2

Across TCGA pan-cancer cohorts, TRBV26OR9-2 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of TRBV26OR9-2’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where TRBV26OR9-2 RNA is repressed in tumor relative to normal tissue. In most cancer types TRBV26OR9-2 is over-expressed in tumor, although a few such as BLCA and COAD show the opposite, repressed pattern.

BLCA, COAD, and BRCA are the cancer types where TRBV26OR9-2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TRBV26OR9-2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	IV	−1.000	.007	8	view →
COAD	All	All	−0.437	<.001	8	view →
BRCA	All	II,III,IV	−1.059	<.001	6	view →
READ	All	All	−1.440	<.001	5	view →
STAD	All	All	−0.648	.002	5	view →
KICH	All	II,III,IV	−0.208	.005	5	view →
LUAD	Female	II,III,IV	−0.475	<.001	4	view →
ESCA	All	II,III,IV	−1.755	.005	2	view →
UCEC	All	All	−0.469	.006	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 9 strongest of 9 lineages.

TRBV26OR9-2–BLCA

Open the BLCA breakdown →